IMA for Pharmaceutical
Cell & Gene and High-value, Small Batch Processing Line
Fill-finish processing and gloveless technologies to maximise the value of specialty pharmaceuticals and medicines for cell & gene therapies.
Future-oriented solutions
The ability to integrate new technologies into a line comprising today’s most advanced machines is defining the future of aseptic processing.
An equipment line-up ensuring the best product characteristics, the most efficient processing methods and the versatility to suit a broad variety of demands and packaging options.
TILE-X WINNER OF BIOTECH INNOVATION AT INTERPHEX NY 2025 EXHIBITOR AWARDS
An integrated solution introducing a ground-breaking technology for high-value pharmaceuticals.
Following upstream bag/tub/tray-opening using robotics to minimise operator intervention, the Ready-To-Use component is ready to enter our very latest innovation, TILE-X, a unique, ground-breaking solution providing 100% gloveless processing within its own self-sufficient HVAC system and Grade A environment. Feeding of Ready-To-Use components into the TILE-X modules can be carried out with No-Touch-Transfer technology or other compact solutions for RTU tub/tray surface decontamination. Implementing electromagnetic levitation technology, programmed floating shuttles move the containers to filling and closing stations, and thanks to the flexibility of this system, TILE-X allows implementation of a gloveless modular construction philosophy, where each module handles a single phase of the process: introduction of RTU components, delidding and denesting, filling with 100% check-weighing, capping, and crimping. Perfect for high-value drugs, such as biopharmaceuticals and ATMPs with a focus on cell and gene therapies, with small-batch production, TILE-X processes 40 units/min. and with frictionless component handling, zero particulate is generated. Subsequent processing and packaging stages are fully integrated into this ground-breaking line.
TILE-X
TILE-X represents a revolutionary approach to the production of high value-added drugs, enabling the customisation required for advanced therapy products. These may include Cell & Gene therapies, advanced biological products, stem cell-based drugs and more generally small batches of customised drugs.




